``China Medical Beigang Hospital '' and "Asia University Hospital" received respective approvals for "Stage IV solid cancer" and "Stage I to III solid cancers after ineffective conventional treatments'' by autologous dendritic cells on December 26, 2019.

``China Medical Beigang Hospital '' and "Asia University Hospital" received respective approvals for "Stage IV solid cancer" and "Stage I to III solid cancers after ineffective conventional treatments'' by autologous dendritic cells on December 26, 2019. 

In the cell therapy approvals under the Regulations on Governing Specific Cellular Therapeutic Technology, Ever Supreme's collaborating medical institutes "China Medical Beigang Hospital" and "Asia University Hospital'' received respective approvals for "Stage IV solid cancer" and "Stage I to III solid cancers after ineffective conventional treatments'' by autologous dendritic cells on December 26, 2019.  The approvals provided patients who meet the criteria for admission of the therapy.

BACK